tirzepatide cardiovascular outcomes trial 2024 In patients with type 2 diabetes and atherosclerotic disease, was noninferior to dulaglutide with respect to major cardiovascular events. ⁣, ⁣, Read the full SURPASS-CVOT 🚨 Breaking News: Real-World Data

The FDA labeling for Wegovy, Saxenda, and Zepbound includes warnings about monitoring for depression, suicidal thoughts, and suicidal behavior, which is particularly relevant for patients already taking antidepressants

I've lost 30 pounds since officially starting in June. Rita G., 71 Verified MDWatch member Getting started is simple Qualifying Medicare patients can get FDA-approved GLP-1s for as little as a $50 copay through the Bridge Program

Immunohistochemical and morphometric analysis of effects of Vilon and Epithalon on functional morphology of radiosensitive organs

Here are signs that your dose may need adjustment: Signs the dose is too high: Persistent nausea beyond 3 weeks at current dose level Regular vomiting (more than once per week) Severe constipation not responding to hydration and fiber Food aversion (inability to eat adequate nutrition) Rapid weight loss exceeding 1.5% of body weight per week Signs the dose is too low: No noticeable change in appetite or satiety Minimal or no reduction in food intake Weight has plateaued for 4 or more weeks No gastrointestinal effects whatsoever (some mild effects indicate the drug is working) Signs you are at the right dose: Moderate appetite suppression (eating less without feeling starved) Steady, sustainable weight changes Mild or no side effects Improved satiety (feeling satisfied with smaller portions) Stable energy levels throughout the day Finding the right dose is a process